Vaxart/$VXRT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxart
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Ticker
$VXRT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
105
ISIN
US92243A2006
Website
Vaxart Metrics
BasicAdvanced
$113M
-
-$0.27
1.15
-
Price and volume
Market cap
$113M
Beta
1.15
52-week high
$0.98
52-week low
$0.29
Average daily volume
6.7M
Financial strength
Current ratio
0.636
Quick ratio
0.589
Long term debt to equity
30.65
Total debt to equity
45.072
Interest coverage (TTM)
-18.08%
Profitability
EBITDA (TTM)
-48.238
Gross margin (TTM)
-81.34%
Net profit margin (TTM)
-122.63%
Operating margin (TTM)
-120.60%
Effective tax rate (TTM)
-0.54%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-28.90%
Return on equity (TTM)
-114.74%
Valuation
Price to revenue (TTM)
2.263
Price to book
2.47
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-3.181
Free cash flow yield (TTM)
-31.44%
Free cash flow per share (TTM)
-15.55%
Growth
Revenue change (TTM)
433.43%
Earnings per share change (TTM)
-49.78%
3-year revenue growth (CAGR)
365.13%
3-year earnings per share growth (CAGR)
-25.25%
What the Analysts think about Vaxart
Analyst ratings (Buy, Hold, Sell) for Vaxart stock.
Vaxart Financial Performance
Revenues and expenses
Vaxart Earnings Performance
Company profitability
Vaxart News
AllArticlesVideos
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
GlobeNewsWire·2 weeks ago
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
GlobeNewsWire·3 weeks ago
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxart stock?
Vaxart (VXRT) has a market cap of $113M as of June 30, 2025.
What is the P/E ratio for Vaxart stock?
The price to earnings (P/E) ratio for Vaxart (VXRT) stock is 0 as of June 30, 2025.
Does Vaxart stock pay dividends?
No, Vaxart (VXRT) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Vaxart dividend payment date?
Vaxart (VXRT) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxart?
Vaxart (VXRT) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.